Form 4: Ginkgo Bioworks Insider Trades: Barry Canton Sells Shares

Barry Canton, a director at Ginkgo Bioworks Holdings, Inc., reported transactions involving Class A Common Stock and performance-based restricted stock units.

Summary

• Barry Canton, a director and 10% owner of Ginkgo Bioworks Holdings, Inc. (DNA), engaged in several transactions on April 9th and 10th, 2026.
• On April 9, 2026, 251,786 shares of Class A Common Stock were acquired through the vesting of performance-based restricted stock units (PSUs).
• These PSUs were granted on June 19, 2025, with a target based on a company-wide cash flow reduction over the 2025 calendar year.
• The actual performance achieved was 67% of the target, resulting in the distribution of Class A Common Stock.
• On April 10, 2026, Canton's spouse sold 124,727 shares of Class A Common Stock at $6.434 per share.
• This sale was to cover tax withholding obligations related to the vesting of PSUs, as permitted by the company's equity incentive plans.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting standard insider transactions related to compensation and tax obligations rather than significant strategic shifts or performance indicators.

Positives

• Vesting of 251,786 performance-based restricted stock units indicates progress towards company performance targets.
• The company's equity incentive plans allow for 'sell to cover' transactions to manage tax obligations, demonstrating a structured approach to compensation.

Negatives

• Sale of 124,727 shares by the reporting person's spouse to cover tax withholding obligations, reducing direct beneficial ownership.

Risks

• The performance of PSUs was certified at 67% of the target, indicating that the company did not fully meet its cash flow reduction goals for the period.
• Sales to cover tax withholding obligations, while standard, represent a reduction in insider holdings.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. However, the performance of the PSUs was tied to a company-wide cash flow reduction target, suggesting that cash flow management is a key focus for the company.

Management Comments

• Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person's spouse.
• The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a 'sell to cover' transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The details of PSU vesting and subsequent 'sell to cover' sales are common in the biotechnology and life sciences sector, where performance-based compensation is prevalent and often tied to specific financial or operational milestones.

Related Party Transactions

• Sale of 124,727 shares by Barry Canton's spouse to cover tax withholding obligations related to PSU vesting.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even for tax purposes, can be perceived negatively, although it is a common practice.
• Employees: The structure of compensation through PSUs and the ability to cover taxes through 'sell to cover' transactions are part of the company's employee incentive framework.

Next Steps

• The company's Compensation Committee has certified the performance results related to the PSUs.
• Further PSU grants and vesting events may occur based on future performance targets.

Key Dates

Keywords

Ginkgo Bioworks, DNA, Form 4, Insider Trading, Barry Canton, Restricted Stock Units, PSUs, Class A Common Stock, Securities Exchange Act, Beneficial Ownership